MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; OTCBB: OCAT), a leader in the field of Regenerative OphthalmologyTM, today announced that the United States Patent and Trademark Office (USPTO) issued two U.S. Patents, Nos. 8,962,321 and 8,961,956, directed to the Company’s Hemangio-derived Mesenchymal Cells (“HMCs”). Ocata’s HMC technology introduces a new era of cell therapy for ophthalmic, autoimmune and inflammatory diseases. This development enables the generation of a potentially unlimited supply of potent HMCs from renewable pluripotent stem cell sources. In addition to HMC formulations, the issued patents also broadly protect the manufacture of HMCs as well as the therapeutic use of these cells in the treatment of ophthalmic, autoimmune and inflammatory diseases.